Solid Biosciences
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 months.
- Its last 4 Sell calls were followed by a 16% average decline over the next quarter.
- Recent price momentum is +4.4% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 12.4% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability F
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | -1,226.5% | Better than 3% |
| Net margin | -1,062.3% | Better than 2% |
| Return on equity | -109.9% | Better than 5% |
| Return on invested capital | -101.7% | Better than 2% |
Momentum C
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -32.8% | Better than 16% |
| 6-month return | -5.6% | Better than 46% |
| 12-month return (ex latest month) | 31.7% | Better than 71% |
| Distance below 52-week high | 45.4% | Better than 23% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 6.1x | Better than 89% |
| Debt to assets | 9.1% | Better than 71% |
| Interest coverage | -365.8x | Better than 3% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 188.0% | Better than 94% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 6.44
- Open
- 6.34
- Day range
- 6.20 - 6.53
- Avg price
- 6.29
- Volume
- 1.56M
- Turnover
- 9.81M
- Turnover ratei
- 2.46%
- Volume ratioi
- 1.31
- Amplitudei
- 5.20%
- 52-week rangei
- 4.65 - 11.45
Valuation
- P/Ei
- -3.14
- P/E (TTM)i
- -3.55
- P/Bi
- 2.04
- EPSi
- -1.99
- Book value / shi
- 3.07
- Net profit
- -222.10M
- Net assets
- 342.09M
Share structure
- Market cap
- 697.57M
- Float capi
- 395.50M
- Shares out
- 111.61M
- Float sharesi
- 63.28M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2018-01-25
45.4% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-8.98M net over the window
Short interest
- Shares short
- 13.30M
- % of floati
- 12.41%
- Days to coveri
- 10.71
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Solid Biosciences (SLDB)?
Solid Biosciences last traded at 6.25. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Solid Biosciences's market cap?
About 697.57M.
What is the P/E ratio of Solid Biosciences?
The trailing twelve-month P/E is -3.55. The Valuation tab shows it against the stock's own five-year range.
Does Solid Biosciences pay a dividend?
Solid Biosciences does not currently pay a regular dividend.
Is Solid Biosciences a buy according to analysts?
The consensus of 11 analysts is a Buy rating, with an average 12-month price target of 18.00, which implies 188.0% upside from the current price. This is not investment advice.
What is Solid Biosciences's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Solid Biosciences a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Solid Biosciences discussion 0 comments